View Financial HealthGenflow Biosciences 配当と自社株買い配当金 基準チェック /06Genflow Biosciences配当金を支払った記録がありません。主要情報n/a配当利回り-11.1%バイバック利回り総株主利回り-11.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 13Genflow Biosciences Plc Announces International Patent Publication For Sirt6-Based Muscular Disease ProgramGenflow Biosciences Plc had announced the international publication of its Patent Cooperation Treaty (PCT) application, WO 2026/062177 A1, entitled "Variants of Sirtuin 6 for the Treatment of Muscular Diseases." The published PCT application relates to variants of SIRT6 for the prevention and treatment of muscular diseases, with particular focus on frailty syndrome and sarcopenia. The application describes compositions and methods involving SIRT6 variants, including nucleic acids, polypeptides, vectors and pharmaceutical compositions intended for use in muscular disease settings associated with loss of muscle mass and altered endocrine function of the muscle. This international publication represents an important milestone in Genflow's intellectual property strategy and broadens the potential protection surrounding the Company's SIRT6 platform beyond longevity and metabolic applications. By advancing patent coverage into muscular diseases, Genflow is further strengthening the proprietary foundation of its platform while opening additional potential therapeutic pathways for development and partnering. The publication enhances the visibility and scope of Genflow's IP estate at an international level. It supports the Company's strategy of building layered protection around the therapeutic use of SIRT6 variants across multiple age-related indications. The PCT publication also preserves Genflow's ability to pursue patent protection across multiple jurisdictions, supporting development flexibility and potential discussions with pharmaceutical and biotech partners. Taken together, this publication reinforces the depth of the Company's scientific platform and the continued expansion of its intellectual property backbone. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.お知らせ • Apr 10Genflow Biosciences plc Reports Sustained Safety and Efficacy Three Months Post Dosing in Slab TrialGenflow Biosciences Plc highlighted continued positive safety and efficacy signals from its ongoing SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene therapy. Follow-up observations conducted three months after the initial dosing period confirm that previously reported improvements have been maintained. No adverse events have been observed, and the therapy continues to demonstrate a favourable safety and tolerability profile in aged dogs. These findings build on the Company's previously announced interim results and provide early evidence supporting the durability of the therapy's effects. Improvements across multiple independent endpoints remain consistent with earlier observations, while control animals continue to exhibit expected age-related decline. The SLAB study remains ongoing, with all dogs continuing to be actively monitored and evaluated. The trial is expected to continue for a further four months, with completion anticipated at the end of July 2026. Additional analyses, including methylation clock (biological age) assessment and muscle histology, are in progress and are expected to provide further mechanistic and quantitative insight into the therapy's impact. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.お知らせ • Mar 06Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.8 million.Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 42,105,263 Price\Range: £0.019 Security Features: Attached Warrantsお知らせ • Mar 03Genflow Biosciences plc Confirms Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 DevelopmentGenflow Biosciences Plc confirmed receipt of the first instalment of €336,467 of the previously announced €4 million non-dilutive grant awarded by the Wallonia Region of Belgium. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap for GF-1002 in MASH. The grant will support the continued development of the Company's lead gene therapy candidate, GF-1002, with further instalments expected to be received in accordance with the agreed milestone and disbursement schedule. The first instalment has been received and will be applied toward eligible project-related activities.お知らせ • Feb 13Genflow Biosciences plc Announces Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged DogsGenflow Biosciences Plc announced positive preliminary interim results from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene therapy in aged dogs. Trial overview The randomised, blinded study, conducted by an independent contract research organisation, enrolled 24 beagle dogs aged over 10 years who were allocated to four groups: two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 cohort, and a control group. The interim analysis reflects outcomes observed during the dosing period. Additional endpoints remain under assessment. All treatment groups demonstrated superior survival compared to the control group during the dosing period. No adverse events were observed, and all treatment modalities exhibited a favourable safety and tolerability profile suitable for use in aged companion animals. Across treatment cohorts, improvements were observed in several functional and observable endpoints, including quality of life, muscle mass preservation, frailty index reduction, and coat quality, relative to control animals, which exhibited expected age-related decline. Ongoing analyses Several key endpoints remain under evaluation, including biological age determination using methylation clock analysis and comprehensive muscle biopsy histology.お知らせ • Jan 19Genflow Biosciences plc Announces Appointment of Gad Berdugo as Independent Non-Executive ChairmanGenflow Biosciences Plc announced a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: Co-Founder & CEO, EpiVax Oncology; Vice-Chairman of the Board, Evexta Bio; Chief Business Officer, Editas Medicine; Chief Business Officer, Nutcracker Therapeutics. He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance.お知らせ • Oct 24Genflow Biosciences plc Announces Publication of Second European Patent Application - SIRT6 Variant for NASHGenflow Biosciences Plc announced that its second European patent application (Application No. 23821586.7, Publication No. EP4630038) titled "SIRT6 Variant for NASH" has been published in the European Patent Bulletin ("EPO"). Publication of the patent application in the European Patent Bulletin follows entry into the European phase under the Patent Cooperation Treaty (PCT) and represents a key milestone in Genflow's expanding intellectual property (IP) portfolio. This publication confers provisional protection under Article 67(3) of the European Patent Convention (EPC), enabling Genflow to claim retroactive damages in designated EPC states for infringing acts occurring after the publication date, once the patent is formally granted and national validation requirements are met. This development marks continued progress in Genflow's comprehensive patent strategy to strengthen protection for its SIRT6 gene variant technologies and expand their therapeutic reach across metabolic and age-related disorders, including NASH (non-alcoholic steatohepatitis). It also reinforces Genflow's IP leadership in the longevity and metabolic disease space, complementing the recently published EP4338267 covering the Company's core SIRT6 variant for healthy aging. Together, these filings establish a robust European patent framework supporting Genflow's therapeutic platform and upcoming clinical programs.お知らせ • Oct 04Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.34 million.Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.34 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 40,000,000 Price\Range: £0.0085お知らせ • Aug 18Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects ReportedGenflow Biosciences Plc provided an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs. The randomized, controlled trial, conducted with CRO Syngene, involves 28 beagles aged 10+ years. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects, while controls remain untreated. The dogs will now enter a five-month follow-up period expected to conclude in January 2026. The strategic goal of this proof-of-concept trial is to generate compelling preclinical data that will enable a licensing agreement with a leading Animal Health company. GF-1004 is a first-in-class gene therapy candidate targeting fundamental aging mechanisms shared by both dogs and humans. By intervening at the mitochondrial and epigenetic levels, GF-1004 offers the potential to not only extend lifespan, but also improve the quality of life in companion animals, a rapidly growing, high-value market segment. Study objectives are to: Confirm feasibility of GF-1004 administration in the target population. Validate safety and efficacy at the proposed administered dose. Demonstrate multi-dimensional benefits relevant to both clinical outcomes and consumer appeal, including: Reduced biological age (GRIM methylation clock); Increased muscle strength and mass; Enhanced mitochondrial function; Improved coat quality; Better overall health metrics; Translational Potential; Since dogs and humans share conserved aging pathways, success in this trial will provide a strong foundation for expansion into human health applications, unlocking additional markets in longevity therapeutics.お知らせ • Jul 25Genflow Biosciences plc Reports Key Preclinical Activities in Two of Its Lead ProgramsGenflow Biosciences Plc reported key preclinical activities in two of its lead programs. GF-1002 In preparation for a submission for European Clinical Trial Authorisation (CTA), the EU's regulatory equivalent to the U.S. FDA's IND process, Genflow is continuing to advance key development activities. To support this process, the Company has initiated Chemistry, Manufacturing, and Controls (CMC) work in collaboration with its CDMO partner, Exothera, to ensure clinical supply production meets Good Manufacturing Practice (GMP) standards. In parallel, pivotal efficacy studies are underway with Genflow's independent CRO partners, Physiogenex and Accelera, evaluating GF-1002 in both early and advanced stages of MASH. GF-1004 Genflow has submitted a first protocol amendment to its ongoing proof-of-concept clinical trial in aged dogs to clarify the administration of its investigational product, GF-1004. The amended protocol now specifies the intravenous (IV) dose rate to ensure consistent and controlled delivery, minimizing the risk of infusion-related adverse events and reinforcing patient safety. This randomized, controlled trial initiated in March in collaboration with the renowned CRO, Syngene is designed to evaluate the safety and efficacy of Genflow's proprietary SIRT6-centenarian gene therapy in addressing age-related decline in dogs.お知らせ • May 23Genflow Biosciences plc, Annual General Meeting, Jun 12, 2025Genflow Biosciences plc, Annual General Meeting, Jun 12, 2025. Location: 1 heddon street, w1b 4bd, london United Kingdomお知らせ • Apr 10Genflow Biosciences plc Launches New Ophthalmology Development ProgramGenflow Biosciences Plc announced the launch of a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6). This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma. This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT 6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector to target ocular diseases. These therapies will leverage Genflow's proprietary SIRT6 Centenarian gene technology, in combination with an advanced vector delivery system.お知らせ • Mar 28Genflow Biosciences plc has filed a Follow-on Equity Offering in the amount of £0.434084 million.Genflow Biosciences plc has filed a Follow-on Equity Offering in the amount of £0.434084 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,579,429 Price\Range: £0.0105 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,761,905 Price\Range: £0.0105 Transaction Features: Subsequent Direct Listingお知らせ • Jun 27Genflow Biosciences plc Announces Strengthening of Pre-Clinical EffortsGenflow Biosciences plc report advancements in its pre-clinical programs. Genflow has initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP). Genflow is also in the process of selecting Contract Research Organizations (CROs) to conduct its upcoming dog clinical trial, aimed at studying its promising drug candidate, GF-1004. The Company is currently evaluating requests for proposals (RFPs) and is working diligently to finalize a definitive agreement next month. In addition, Genflow has received research guidance from the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT). The Company submitted a comprehensive briefing package detailing all preclinical (in vitro and in vivo) studies conducted with its lead drug candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH). The FDA has encouraged Genflow to proceed with its plans to identify appropriate animal models through pilot proof-of-concept (POC) studies. These studies will inform the definitive POC, toxicology, and biodistribution studies necessary for eventual clinical trials. Detailed summaries of the products used in each animal study and their comparability to the intended clinical product are to be included.お知らせ • Jun 05Genflow Biosciences plc, Annual General Meeting, Jun 27, 2024Genflow Biosciences plc, Annual General Meeting, Jun 27, 2024. Location: 1 heddon street, w1b 4bt, london United Kingdomお知らせ • Apr 04Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.715 million.Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.715 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 57,200,000 Price\Range: £0.0125 Security Features: Attached Warrants Transaction Features: Subsequent Direct Listingお知らせ • Jan 18Genflow Biosciences plc Announces Two Non-Dilutive Research Grant AwardsGenflow Biosciences PLC announced Two Non-Dilutive Research Grant Awards. The Company announced two significant new research programs in collaboration with Revatis SA and EXO Biologics, backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium. Funding for the two research programs, as part of the Wallonia Recovery Plan by the Walloon Government in Belgium, will be disbursed annually to the Company, contingent upon Genflow and its collaborators achieving specific, activity-based milestones. Continued receipt of the grants by Genflow is dependent on the parties meeting predefined criteria each applicable year. The two research programs are a part of a broader innovation partnership that the Walloon Government has launched, dedicated to Advanced Therapy Medicinal Products (ATMPs). The partnership boasts a substantial budget of 81 million euros, a mix of 60% public funding and 40% private contributions from various companies, spread over three years. This initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia and the Public Service of Wallonia, representing a significant commitment to advancing medical research and development in the region. Genflow, together with Revatis SA, has launched a 3-year sarcopenia research program, generously funded by a grant totalling 1.34 million euros. Sarcopenia, the progressive loss of muscle mass and function associated with ageing, poses a significant health risk and affects the quality of life for millions of elderly people worldwide. This collaborative effort aims to expand and diversify Genflow's research pipeline, addressing this growing concern as the global population ages. The partnership will leverage both companies' expertise to develop innovative solutions and contribute valuable insights into the mechanisms of age-related muscle deterioration. Genflow and EXO Biologics have initiated a 3-year scientific program, supported by a grant of 1.55 million euros. The project focuses on the development of a novel mRNA delivery system using exosomes to encapsulate and transport Genflow's proprietary centenarian SIRT6 gene. This cutting-edge approach aims to harness the natural advantages of exosomes, such as enhanced stability, improved cellular uptake, reduced immunogenicity, minimal toxicity, natural cargo sorting and reduced off-target effects, among others. This endeavour not only demonstrates Genflow's momentum in leading-edge research, but also holds the potential to revolutionize therapeutic interventions for Werner Syndrome, an accelerated ageing condition and holds great promised for a range of other age-related conditions.お知らせ • Sep 20Genflow Biosciences Plc Announces Company UpdateGenflow Biosciences Plc announced the receipt of written comments from the Federal Agency for Medicines and Health Products (FAHMP) of Belgium. The Company is pleased with the advice received from the FAHMP to commence clinical trials of its drug, GF-1002, with patients suffering from NASH (rather than in healthy volunteers). This follows promising results from the Company's research in in-vitro human cells and in-vivo rodent studies. The Company's NASH clinical trials are scheduled to begin in approximately 18 months following dialogue and subsequent agreement with the European Medicine Agency.決済の安定と成長配当データの取得安定した配当: GENF.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: GENF.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Genflow Biosciences 配当利回り対市場GENF.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (GENF.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (GENF.F) (最長3年)n/a注目すべき配当: GENF.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: GENF.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: GENF.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: GENF.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 07:54終値2026/05/19 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genflow Biosciences plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 13Genflow Biosciences Plc Announces International Patent Publication For Sirt6-Based Muscular Disease ProgramGenflow Biosciences Plc had announced the international publication of its Patent Cooperation Treaty (PCT) application, WO 2026/062177 A1, entitled "Variants of Sirtuin 6 for the Treatment of Muscular Diseases." The published PCT application relates to variants of SIRT6 for the prevention and treatment of muscular diseases, with particular focus on frailty syndrome and sarcopenia. The application describes compositions and methods involving SIRT6 variants, including nucleic acids, polypeptides, vectors and pharmaceutical compositions intended for use in muscular disease settings associated with loss of muscle mass and altered endocrine function of the muscle. This international publication represents an important milestone in Genflow's intellectual property strategy and broadens the potential protection surrounding the Company's SIRT6 platform beyond longevity and metabolic applications. By advancing patent coverage into muscular diseases, Genflow is further strengthening the proprietary foundation of its platform while opening additional potential therapeutic pathways for development and partnering. The publication enhances the visibility and scope of Genflow's IP estate at an international level. It supports the Company's strategy of building layered protection around the therapeutic use of SIRT6 variants across multiple age-related indications. The PCT publication also preserves Genflow's ability to pursue patent protection across multiple jurisdictions, supporting development flexibility and potential discussions with pharmaceutical and biotech partners. Taken together, this publication reinforces the depth of the Company's scientific platform and the continued expansion of its intellectual property backbone. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.
お知らせ • Apr 10Genflow Biosciences plc Reports Sustained Safety and Efficacy Three Months Post Dosing in Slab TrialGenflow Biosciences Plc highlighted continued positive safety and efficacy signals from its ongoing SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene therapy. Follow-up observations conducted three months after the initial dosing period confirm that previously reported improvements have been maintained. No adverse events have been observed, and the therapy continues to demonstrate a favourable safety and tolerability profile in aged dogs. These findings build on the Company's previously announced interim results and provide early evidence supporting the durability of the therapy's effects. Improvements across multiple independent endpoints remain consistent with earlier observations, while control animals continue to exhibit expected age-related decline. The SLAB study remains ongoing, with all dogs continuing to be actively monitored and evaluated. The trial is expected to continue for a further four months, with completion anticipated at the end of July 2026. Additional analyses, including methylation clock (biological age) assessment and muscle histology, are in progress and are expected to provide further mechanistic and quantitative insight into the therapy's impact. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.
お知らせ • Mar 06Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.8 million.Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 42,105,263 Price\Range: £0.019 Security Features: Attached Warrants
お知らせ • Mar 03Genflow Biosciences plc Confirms Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 DevelopmentGenflow Biosciences Plc confirmed receipt of the first instalment of €336,467 of the previously announced €4 million non-dilutive grant awarded by the Wallonia Region of Belgium. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap for GF-1002 in MASH. The grant will support the continued development of the Company's lead gene therapy candidate, GF-1002, with further instalments expected to be received in accordance with the agreed milestone and disbursement schedule. The first instalment has been received and will be applied toward eligible project-related activities.
お知らせ • Feb 13Genflow Biosciences plc Announces Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged DogsGenflow Biosciences Plc announced positive preliminary interim results from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene therapy in aged dogs. Trial overview The randomised, blinded study, conducted by an independent contract research organisation, enrolled 24 beagle dogs aged over 10 years who were allocated to four groups: two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 cohort, and a control group. The interim analysis reflects outcomes observed during the dosing period. Additional endpoints remain under assessment. All treatment groups demonstrated superior survival compared to the control group during the dosing period. No adverse events were observed, and all treatment modalities exhibited a favourable safety and tolerability profile suitable for use in aged companion animals. Across treatment cohorts, improvements were observed in several functional and observable endpoints, including quality of life, muscle mass preservation, frailty index reduction, and coat quality, relative to control animals, which exhibited expected age-related decline. Ongoing analyses Several key endpoints remain under evaluation, including biological age determination using methylation clock analysis and comprehensive muscle biopsy histology.
お知らせ • Jan 19Genflow Biosciences plc Announces Appointment of Gad Berdugo as Independent Non-Executive ChairmanGenflow Biosciences Plc announced a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: Co-Founder & CEO, EpiVax Oncology; Vice-Chairman of the Board, Evexta Bio; Chief Business Officer, Editas Medicine; Chief Business Officer, Nutcracker Therapeutics. He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance.
お知らせ • Oct 24Genflow Biosciences plc Announces Publication of Second European Patent Application - SIRT6 Variant for NASHGenflow Biosciences Plc announced that its second European patent application (Application No. 23821586.7, Publication No. EP4630038) titled "SIRT6 Variant for NASH" has been published in the European Patent Bulletin ("EPO"). Publication of the patent application in the European Patent Bulletin follows entry into the European phase under the Patent Cooperation Treaty (PCT) and represents a key milestone in Genflow's expanding intellectual property (IP) portfolio. This publication confers provisional protection under Article 67(3) of the European Patent Convention (EPC), enabling Genflow to claim retroactive damages in designated EPC states for infringing acts occurring after the publication date, once the patent is formally granted and national validation requirements are met. This development marks continued progress in Genflow's comprehensive patent strategy to strengthen protection for its SIRT6 gene variant technologies and expand their therapeutic reach across metabolic and age-related disorders, including NASH (non-alcoholic steatohepatitis). It also reinforces Genflow's IP leadership in the longevity and metabolic disease space, complementing the recently published EP4338267 covering the Company's core SIRT6 variant for healthy aging. Together, these filings establish a robust European patent framework supporting Genflow's therapeutic platform and upcoming clinical programs.
お知らせ • Oct 04Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.34 million.Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.34 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 40,000,000 Price\Range: £0.0085
お知らせ • Aug 18Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects ReportedGenflow Biosciences Plc provided an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs. The randomized, controlled trial, conducted with CRO Syngene, involves 28 beagles aged 10+ years. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects, while controls remain untreated. The dogs will now enter a five-month follow-up period expected to conclude in January 2026. The strategic goal of this proof-of-concept trial is to generate compelling preclinical data that will enable a licensing agreement with a leading Animal Health company. GF-1004 is a first-in-class gene therapy candidate targeting fundamental aging mechanisms shared by both dogs and humans. By intervening at the mitochondrial and epigenetic levels, GF-1004 offers the potential to not only extend lifespan, but also improve the quality of life in companion animals, a rapidly growing, high-value market segment. Study objectives are to: Confirm feasibility of GF-1004 administration in the target population. Validate safety and efficacy at the proposed administered dose. Demonstrate multi-dimensional benefits relevant to both clinical outcomes and consumer appeal, including: Reduced biological age (GRIM methylation clock); Increased muscle strength and mass; Enhanced mitochondrial function; Improved coat quality; Better overall health metrics; Translational Potential; Since dogs and humans share conserved aging pathways, success in this trial will provide a strong foundation for expansion into human health applications, unlocking additional markets in longevity therapeutics.
お知らせ • Jul 25Genflow Biosciences plc Reports Key Preclinical Activities in Two of Its Lead ProgramsGenflow Biosciences Plc reported key preclinical activities in two of its lead programs. GF-1002 In preparation for a submission for European Clinical Trial Authorisation (CTA), the EU's regulatory equivalent to the U.S. FDA's IND process, Genflow is continuing to advance key development activities. To support this process, the Company has initiated Chemistry, Manufacturing, and Controls (CMC) work in collaboration with its CDMO partner, Exothera, to ensure clinical supply production meets Good Manufacturing Practice (GMP) standards. In parallel, pivotal efficacy studies are underway with Genflow's independent CRO partners, Physiogenex and Accelera, evaluating GF-1002 in both early and advanced stages of MASH. GF-1004 Genflow has submitted a first protocol amendment to its ongoing proof-of-concept clinical trial in aged dogs to clarify the administration of its investigational product, GF-1004. The amended protocol now specifies the intravenous (IV) dose rate to ensure consistent and controlled delivery, minimizing the risk of infusion-related adverse events and reinforcing patient safety. This randomized, controlled trial initiated in March in collaboration with the renowned CRO, Syngene is designed to evaluate the safety and efficacy of Genflow's proprietary SIRT6-centenarian gene therapy in addressing age-related decline in dogs.
お知らせ • May 23Genflow Biosciences plc, Annual General Meeting, Jun 12, 2025Genflow Biosciences plc, Annual General Meeting, Jun 12, 2025. Location: 1 heddon street, w1b 4bd, london United Kingdom
お知らせ • Apr 10Genflow Biosciences plc Launches New Ophthalmology Development ProgramGenflow Biosciences Plc announced the launch of a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6). This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma. This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT 6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector to target ocular diseases. These therapies will leverage Genflow's proprietary SIRT6 Centenarian gene technology, in combination with an advanced vector delivery system.
お知らせ • Mar 28Genflow Biosciences plc has filed a Follow-on Equity Offering in the amount of £0.434084 million.Genflow Biosciences plc has filed a Follow-on Equity Offering in the amount of £0.434084 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,579,429 Price\Range: £0.0105 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,761,905 Price\Range: £0.0105 Transaction Features: Subsequent Direct Listing
お知らせ • Jun 27Genflow Biosciences plc Announces Strengthening of Pre-Clinical EffortsGenflow Biosciences plc report advancements in its pre-clinical programs. Genflow has initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP). Genflow is also in the process of selecting Contract Research Organizations (CROs) to conduct its upcoming dog clinical trial, aimed at studying its promising drug candidate, GF-1004. The Company is currently evaluating requests for proposals (RFPs) and is working diligently to finalize a definitive agreement next month. In addition, Genflow has received research guidance from the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT). The Company submitted a comprehensive briefing package detailing all preclinical (in vitro and in vivo) studies conducted with its lead drug candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH). The FDA has encouraged Genflow to proceed with its plans to identify appropriate animal models through pilot proof-of-concept (POC) studies. These studies will inform the definitive POC, toxicology, and biodistribution studies necessary for eventual clinical trials. Detailed summaries of the products used in each animal study and their comparability to the intended clinical product are to be included.
お知らせ • Jun 05Genflow Biosciences plc, Annual General Meeting, Jun 27, 2024Genflow Biosciences plc, Annual General Meeting, Jun 27, 2024. Location: 1 heddon street, w1b 4bt, london United Kingdom
お知らせ • Apr 04Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.715 million.Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.715 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 57,200,000 Price\Range: £0.0125 Security Features: Attached Warrants Transaction Features: Subsequent Direct Listing
お知らせ • Jan 18Genflow Biosciences plc Announces Two Non-Dilutive Research Grant AwardsGenflow Biosciences PLC announced Two Non-Dilutive Research Grant Awards. The Company announced two significant new research programs in collaboration with Revatis SA and EXO Biologics, backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium. Funding for the two research programs, as part of the Wallonia Recovery Plan by the Walloon Government in Belgium, will be disbursed annually to the Company, contingent upon Genflow and its collaborators achieving specific, activity-based milestones. Continued receipt of the grants by Genflow is dependent on the parties meeting predefined criteria each applicable year. The two research programs are a part of a broader innovation partnership that the Walloon Government has launched, dedicated to Advanced Therapy Medicinal Products (ATMPs). The partnership boasts a substantial budget of 81 million euros, a mix of 60% public funding and 40% private contributions from various companies, spread over three years. This initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia and the Public Service of Wallonia, representing a significant commitment to advancing medical research and development in the region. Genflow, together with Revatis SA, has launched a 3-year sarcopenia research program, generously funded by a grant totalling 1.34 million euros. Sarcopenia, the progressive loss of muscle mass and function associated with ageing, poses a significant health risk and affects the quality of life for millions of elderly people worldwide. This collaborative effort aims to expand and diversify Genflow's research pipeline, addressing this growing concern as the global population ages. The partnership will leverage both companies' expertise to develop innovative solutions and contribute valuable insights into the mechanisms of age-related muscle deterioration. Genflow and EXO Biologics have initiated a 3-year scientific program, supported by a grant of 1.55 million euros. The project focuses on the development of a novel mRNA delivery system using exosomes to encapsulate and transport Genflow's proprietary centenarian SIRT6 gene. This cutting-edge approach aims to harness the natural advantages of exosomes, such as enhanced stability, improved cellular uptake, reduced immunogenicity, minimal toxicity, natural cargo sorting and reduced off-target effects, among others. This endeavour not only demonstrates Genflow's momentum in leading-edge research, but also holds the potential to revolutionize therapeutic interventions for Werner Syndrome, an accelerated ageing condition and holds great promised for a range of other age-related conditions.
お知らせ • Sep 20Genflow Biosciences Plc Announces Company UpdateGenflow Biosciences Plc announced the receipt of written comments from the Federal Agency for Medicines and Health Products (FAHMP) of Belgium. The Company is pleased with the advice received from the FAHMP to commence clinical trials of its drug, GF-1002, with patients suffering from NASH (rather than in healthy volunteers). This follows promising results from the Company's research in in-vitro human cells and in-vivo rodent studies. The Company's NASH clinical trials are scheduled to begin in approximately 18 months following dialogue and subsequent agreement with the European Medicine Agency.